
131.7K
Downloads
270
Episodes
Molecule to Market takes you inside the global pharma and biopharma outsourcing ecosystem. Each week, our host Raman Sehgal sits down with the founders, entrepreneurs, CEOs and C-suite leaders shaping the pharma services and tools that power discovery, drug development and commercialization.
Listeners get real stories and practical insights from across the entire value chain, from big pharma and emerging biotechs to private equity investors, CROs, CDMOs, technology platforms and specialist consulting firms. Our host Raman is an entrepreneur, investor, bestselling author, speaker and long time industry insider.
https://moleculetomarketpod.com
Molecule to Market takes you inside the global pharma and biopharma outsourcing ecosystem. Each week, our host Raman Sehgal sits down with the founders, entrepreneurs, CEOs and C-suite leaders shaping the pharma services and tools that power discovery, drug development and commercialization.
Listeners get real stories and practical insights from across the entire value chain, from big pharma and emerging biotechs to private equity investors, CROs, CDMOs, technology platforms and specialist consulting firms. Our host Raman is an entrepreneur, investor, bestselling author, speaker and long time industry insider.
Episodes

Friday Apr 10, 2026
The Indiana boy driving CGT development
Friday Apr 10, 2026
Friday Apr 10, 2026
In this episode of Molecule to Market, you’ll go inside the outsourcing space of the global drug development sector with Sean Werner, Chief Technology Officer at BioLife Solutions,
Your host, Raman Sehgal, discusses the pharmaceutical and biotechnology supply chain with Sean, covering:
- The value of learning your craft in big pharma, and the steep transition from technical expert to President of a spinout
- Why BioLife moved from board involvement to acquiring Sean’s company outright
- The critical role of cryopreservation, and why it remains an overlooked risk in cell therapy development
- His perspective on the cell and gene therapy space, and why there is still plenty of reason for optimism
- The rise of China’s biotech ecosystem and why its growth is a positive for the global industry
- Why CGT is set to diverge into more specialised areas, unlocking new therapeutic and patient applications
Sean Werner is the Chief Technology Officer at BioLife Solutions, a leading provider of bioproduction tools and services to the cell and gene therapy and broader biopharma markets. BioLife acquired Sexton Biotechnologies in 2021 where Sean was President of the company known for providing processing and handling solutions for the CGT industry. Sean received his PhD from Purdue University in Biology followed by post-doctoral positions at the Indiana University School of Medicine and Eli Lilly. Sean has previous experience filling various roles in the scientific, global regulatory, and general management functions supporting medical devices, autologous cell therapy, and single use disposable development programs. In his 23 years working in the life science industry, he has guided regenerative medicine research programs, pre-clinical and clinical testing and submission strategies leading to global commercialization of medical devices and bioprocessing tools and successful initiation of multi-national cell therapy clinical studies.
Molecule to Market is also sponsored by Bora Pharmaceuticals and supported by Lead Candidate. Please subscribe, tell your industry colleagues and join us in celebrating and promoting the value and importance of the global life science outsourcing space. We’d also appreciate a positive rating!

No comments yet. Be the first to say something!